It looks like Cheryl has taken her broom into the office and cleaned out some of the rubbish. Astra Zeneca - OUT, Chase Sun - OUT. Pity she missed the references in the “About Starpharma” summary. They will disappear soon, hopefully along with that horrible word “optionality” so liked by her predecessor.
Now, what are the “difficult decisions and trade-offs “ she is talking about?
Capital raise? I sincerely hope not, not after JF was quite clear that they would not need to go to the market again. But then again, time has moved on and all the big share holders are now not so big holders. Asking the retail holders to throw a lifeline when the SP is still in the deep end is unlikely to get a warm reception.
She talks of “managing costs efficiently to extend the cash runway”. This to me implies that there are no obvious deals in the near future.
She also puts a lot more emphasis on DEP and oncology.
From all of this, I think she wants to sell off SPL7013. If so, Hurrah. Bring it on, sooner the better. The company has wasted so much time, money and reputation trying to commercialise the SPL7013 products when it should have concentrated on DEP. And if it is sold at a bargain price then so be it - not too difficult a decision and a good trade-off would be my opinion.
SPL Price at posting:
12.5¢ Sentiment: Hold Disclosure: Held
